IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.
about
Stimulation of Natural Killer Cell-Mediated Tumor Immunity by an IL15/TGFβ-Neutralizing Fusion Protein.The potential and promise of IL-15 in immuno-oncogenic therapies.IL-2 and Beyond in Cancer Immunotherapy.ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 BlockadeRegulation of Energy Expenditure and Brown/Beige Thermogenic Activity by Interleukins: New Roles for Old Actors
P2860
IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
IL-15 Trans-Signaling with the ...... Activity of PD-1 Antagonists.
@en
type
label
IL-15 Trans-Signaling with the ...... Activity of PD-1 Antagonists.
@en
prefLabel
IL-15 Trans-Signaling with the ...... Activity of PD-1 Antagonists.
@en
P2093
P2860
P50
P356
P1476
IL-15 Trans-Signaling with the ...... r Activity of PD-1 Antagonists
@en
P2093
Géraldine Teppaz
Magali Terme
Yannick Jacques
P2860
P304
P356
10.4049/JIMMUNOL.1600019
P407
P50
P577
2016-05-23T00:00:00Z